Revlimid generics launched in Europe by STADA and Sandoz
The launch of generic versions of Bristol Myers Squibb’s (NYSE: BMY) blockbuster multiple myeloma drug Revlimid (lenalidomide) in Europe have been announced by two companies today.
First, German drugmaker STADA Arzneimittel (SAZ: Xetra) said is broadening its oncology portfolio by introducing a generic alternative to Revlimid capsules in more than a dozen European countries from February 18. Under the terms of a patent-litigation settlement, STADA is now able to offer the multiple myeloma and lymphoma treatment to oncologists and their patients in countries including France, Germany, Italy and Spain.
Patients in Belgium, the Czech Republic, Ireland, the Netherlands, Poland and Portugal are also set to benefit from generic competition to Revlimid, as are patients in Denmark, Finland and Sweden.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze